Silo Pharma, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
CEO Eric Weisblum and CFO Daniel Ryweck certified the Q2 2026 10-Q filed August 13, 2026, attesting that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed. This is routine periodic certification required by Sarbanes-Oxley Section 302 and 906.
Why this rating
Boilerplate SOX certification; standard quarterly regulatory requirement. No operational, financial, or strategic changes disclosed.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.